GSK plc
GSK
$44.98
$0.100.22%
| Weiss Ratings | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B | |||
| Rating Factors | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Fair | |||
| Growth Index | Fair | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.12 | |||
| Price History | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.70% | |||
| 30-Day Total Return | 10.19% | |||
| 60-Day Total Return | 6.59% | |||
| 90-Day Total Return | 12.60% | |||
| Year to Date Total Return | 20.11% | |||
| 1-Year Total Return | 28.57% | |||
| 2-Year Total Return | -23.24% | |||
| 3-Year Total Return | -12.62% | |||
| 5-Year Total Return | -13.19% | |||
| 52-Week High % Change | -2.06% | |||
| 52-Week Low % Change | 34.95% | |||
| Price | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $45.93 | |||
| 52-Week Low Price | $33.33 | |||
| 52-Week Low Price (Date) | Jun 01, 2023 | |||
| 52-Week High Price (Date) | May 15, 2024 | |||
| Valuation | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 91.72B | |||
| Enterprise Value | 108.27B | |||
| Price/Earnings (TTM) | 32.68 | |||
| Earnings Per Share (TTM) | 1.38 | |||
| Earnings Per Share Growth | -67.61% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.79 | |||
| Price/Book (Q) | 10.49 | |||
| Enterprise Value/Revenue (TTM) | 2.80 | |||
| Price | $44.98 | |||
| Enterprise Value/EBITDA (TTM) | 8.35 | |||
| Enterprise Value/EBIT | 10.13 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 4.11B | |||
| Dividend Yield | 3.23% | |||
| Div. Per Share (Most Recent) | $0.37 | |||
| Dividend Per Share (TTM) | $1.45 | |||
| Payout Ratio (TTM) | 50.30% | |||
| Dividend Per Share (Most Recent) | $0.37 | |||
| Company Info | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 44 20 8047 5000 | |||
| Address | -- | |||
| Website | www.gsk.com | |||
| Country | United Kingdom | |||
| Year Founded | 1715 | |||
| Profitability | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 27.66% | |||
| Profit Margin | 14.61% | |||
| Management Effectiveness | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 9.13% | |||
| Return on Equity | 39.03% | |||
| Income Statement | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 38.64B | |||
| Total Revenue (TTM) | 38.64B | |||
| Revenue Per Share | $9.39 | |||
| Gross Profit (TTM) | 27.50B | |||
| EBITDA (TTM) | 12.97B | |||
| EBIT (TTM) | 10.69B | |||
| Net Income (TTM) | 5.65B | |||
| Net Income Avl. to Common (TTM) | 5.65B | |||
| Total Revenue Growth (Q YOY) | 10.62% | |||
| Earnings Growth (Q YOY) | -30.79% | |||
| EPS Diluted (TTM) | 1.38 | |||
| EPS Diluted Growth (Q YOY) | -27.32% | |||
| Balance Sheet | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.17B | |||
| Cash Per Share (Q) | $1.26 | |||
| Total Current Assets (Q) | 21.73B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 16.71B | |||
| Current Ratio (Q) | 0.867 | |||
| Book Value Per Share (Q) | $4.29 | |||
| Total Assets (Q) | 73.90B | |||
| Total Current Liabilities (Q) | 25.07B | |||
| Total Debt (Q) | 22.45B | |||
| Total Liabilities (Q) | 57.19B | |||
| Total Common Equity (Q) | 17.48B | |||
| Cash Flow | GSK - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.68B | |||
| Cash from Financing (TTM) | -8.00B | |||
| Net Change in Cash (TTM) | -169.60M | |||
| Levered Free Cash Flow (TTM) | 6.85B | |||
| Cash from Operations (TTM) | 9.62B | |||
